Death receptor-mediated liver injury.

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00

Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology (2014) 1.73

Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol (2011) 1.22

Apoptosis as a mechanism for liver disease progression. Semin Liver Dis (2010) 1.21

Yes-associated protein regulates the hepatic response after bile duct ligation. Hepatology (2012) 1.15

Apoptosis and necrosis in the liver. Compr Physiol (2013) 1.05

Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2012) 0.96

Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. Liver Int (2009) 0.90

Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma. Medscape J Med (2008) 0.89

Degradation of cIAPs contributes to hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol (2013) 0.87

HBx activates FasL and mediates HepG2 cell apoptosis through MLK3-MKK7-JNKs signal module. World J Gastroenterol (2012) 0.87

The regulatory role of microRNA-1187 in TNF-α-mediated hepatocyte apoptosis in acute liver failure. Int J Mol Med (2012) 0.83

The role of fas/fas ligand system in the pathogenesis of liver cirrhosis and hepatocellular carcinoma. Hepat Mon (2012) 0.81

Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology (2016) 0.80

Significance of increased expression of decoy receptor 3 in chronic liver disease. Dig Liver Dis (2009) 0.80

Amelioration of carbon tetrachloride-induced cirrhosis and portal hypertension in rat using adenoviral gene transfer of Akt. World J Gastroenterol (2013) 0.80

Glycosyltransferases and non-alcoholic fatty liver disease. World J Gastroenterol (2016) 0.76

Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-dependent apoptosis that protect mice from acute liver failure. Cell Death Dis (2016) 0.76

The Characteristics of Antioxidant Activity after Liver Transplantation in Biliary Atresia Patients. Biomed Res Int (2015) 0.75

Apoptosis and hepatic necroinflammation. Gastroenterol Hepatol (N Y) (2008) 0.75

Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci Rep (2017) 0.75

A genetic screen reveals Foxa3 and TNFR1 as key regulators of liver repopulation. Genes Dev (2015) 0.75

Antitumoral gene-based strategy involving nitric oxide synthase type III overexpression in hepatocellular carcinoma. Gene Ther (2015) 0.75

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84

Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13

Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95

Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60

Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57

Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36

Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23

Cholangiocarcinoma. Gastroenterology (2005) 3.15

Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02

Lysosomes in cell death. Oncogene (2004) 3.00

Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89

Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81

Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70

Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63

EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61

Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56

Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51

Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45

Life and death by death receptors. FASEB J (2009) 2.39

Cholangiocarcinoma. Clin Liver Dis (2008) 2.33

Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33

Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31

Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29

Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23

A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23

MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23

Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19

Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18

Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18

Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03

Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03

Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01

Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01

Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99

Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98

Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97

Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96

Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93

Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91

The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88

Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86

A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83

JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82

Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80

Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78

Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73

Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70

Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68

A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol (2004) 1.66

Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol (2006) 1.66

A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65

Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl (2007) 1.64

Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem (2007) 1.63

Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci (2005) 1.63

The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63

Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology (2006) 1.60

The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther (2003) 1.60

Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58

Liver transplantation for cholangiocarcinoma. Transpl Int (2010) 1.58

Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol (2010) 1.56

Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ Res (2002) 1.56

Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology (2009) 1.55

Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol (2012) 1.55

CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.54

Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) (2011) 1.54

Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol (2005) 1.53

Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology (2010) 1.53

IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 1.52

"Will all liver transplantation patients eventually die from cancer?". J Hepatol (2005) 1.52

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol (2012) 1.51

Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol (2003) 1.50

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology (2009) 1.49

Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol (2003) 1.48

Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol (2002) 1.47

The emergence of a new discipline, hepatobiliary oncology. Hepatology (2008) 1.46

TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology (2008) 1.45

Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem (2007) 1.43

Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.43

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol (2013) 1.43

Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation (2006) 1.43

Comparison of methods to detect neoplasia in patients undergoing endoscopic ultrasound-guided fine-needle aspiration. Gastroenterology (2012) 1.43

Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology (2006) 1.42

Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology (2008) 1.41

Primary sclerosing cholangitis: summary of a workshop. Hepatology (2006) 1.38

Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res (2002) 1.37

Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology (2005) 1.37

Death receptor-mediated apoptosis and the liver. J Hepatol (2002) 1.37

Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem (2002) 1.36

Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr (2011) 1.35

Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis (2004) 1.34

Mechanisms of liver injury: an overview. Curr Mol Med (2003) 1.34

Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol (2005) 1.32

Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem (2003) 1.32

Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology (2002) 1.31

Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology (2005) 1.27

The anti-apoptotic protein Mcl-1 inhibits mitochondrial Ca2+ signals. J Biol Chem (2005) 1.24